Claudio Galli

Dr. Claudio Galli

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2006 in Journal of Clinical Virology
Verified
Journal Article
Closed access
PDF file
ARAnna Rodella
Anna Rodella
CGClaudio Galli
Claudio Galli
LTLuigina Terlenghi
Luigina Terlenghi
FPFrancesca Perandin
Francesca Perandin
CBCarlo Bonfanti
Carlo Bonfanti
NMNino Manca
Nino Manca

1 September 1994 in The Lancet
Verified
Journal Article
Closed access
FPFrancescoA. Pisanti
FrancescoA. Pisanti
ACAngelina Coppola
Angelina Coppola
CGClaudio Galli
Claudio Galli

23 April 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Anna Rosa GarbugliaAnna Rosa Garbuglia
Anna Rosa Garbuglia
AMAlessia Monachetti
Alessia Monachetti
CGClaudio Galli
Claudio Galli
RSRosella Sabatini
Rosella Sabatini
MFMonica Lucia Ferreri
Monica Lucia Ferreri
PBPatrizia Bagnarelli
Patrizia Bagnarelli
A good correlation between HCV core antigen (HCVAg) and different HCV-RNA assays has been described, but little data are available in HCV/HIV co-infection. We aimed to evaluate HCVAg in comparison with HCV-RNA and to determine their kinetics during antiviral treatment in selected HCV/HIV co-infected patients. 355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes. The differences between percentages were evaluated by chi square or Fisher’s exact test, while mean and median values were compared by Student’s t test or the Mann–Whitney test, respectively. All differences were considered significant for a p value <0.05. HCVAg was detectable on 288/315 sera (91.4%) positive for HCV-RNA and in 5 out of40 (12.5%) sera with undetectable HCV-RNA for a total concordance of 90.1%. The correlation was fair both in untreated (r = 0.742) and in treated (r = 0.881) patients and stronger for genotypes 1 and 4 than for genotype 3. Both HCV-RNA and HCVAg levels were significantly higher (p = 0.028 and p = 0.0098, respectively) in patients infected by genotype 1 than by genotype 3. The mean ratio of Log values between HCV-RNA (IU/mL) and HCVAg (fmol/liter) was 2.27 ± 1.09 in untreated and 2.20 ± 0.82 in treated patients (p = n.s.),consistent with a sensitivity of HCVAg corresponding to about 1,000 IU/mL of HCV-RNA, and ranged from 2.21 to 2.32 among HCV genotypes with no significant differences; five samples (1.4%; 2 genotype 1a or 1c, 3 genotype 3a) showed highly divergent values. The analysis of 18 monitoring profiles from patients treated with PEG-IFN and Ribavirin showed similar trends, except in one case in which relapse could be predicted by HCVAg and not by HCV-RNA. These results suggest that HCVAg represents an adequate tool for determining an ongoing HCV infection also in HIV co-infected patients, with lower costs and faster turnaround time than HCV-RNA.

27 April 2018 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
CGClaudio Galli
Claudio Galli
PJPaul Julicher
Paul Julicher
Mario PlebaniMario Plebani
Mario Plebani
The diagnosis of hepatitis C virus (HCV) infection has been traditionally based on the detection of the host antibody response. Although antibody assays are available in different formats and are fairly accurate, they cannot distinguish between an ongoing infection with HCV replicative activity and a past infection where HCV has been cleared, spontaneously or after a successful therapy. As a chronic infection is mostly asymptomatic until the late clinical stages, there is a compelling need to detect active HCV infection by simple and reproducible methods. On this purpose, the clinical guidelines have suggested to search for the HCV ribonucleic acid (HCV-RNA) after anti-HCV has been detected, but this second step carries several limitations especially for population screening. The availability of fast and automated serological assays for the hepatitis C core antigen (HCVAg) has prompted an update of the guidelines that now encompass the use of HCVAg as a practical alternative to HCV-RNA, both for screening and monitoring purposes. In this paper, we summarize the features, benefits and limitations of HCVAg testing and provide an updated compendium of the evidences on its clinical utility and on the indications for use.

21 April 2008 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
CGClaudio Galli
Claudio Galli
EOElisa Orlandini
Elisa Orlandini
LPLuigi Penzo
Luigi Penzo
RBRenzo Badiale
Renzo Badiale
GCGiacomo Caltran
Giacomo Caltran
GGGianluca Gessoni
Gianluca Gessoni

1 May 2004 in Journal of Clinical Virology
Verified
Journal Article
Closed access
PDF file
VBVincenzo Bossi
Vincenzo Bossi
CGClaudio Galli
Claudio Galli